Concepedia

Author

Thomas Seck

Heidelberg University

Also Known As

T Seck, T. L. Seck, T. Seck, Thomas L. Seck, Thomas Seck

52

Publications

1.6K

Citations

22

H-Index

44

Concepts

All Affiliations

Heidelberg UniversityMerck & Co., Inc., Rahway, NJ, USA (United States)BG University Hospital Bergmannsheil BochumBoehringer Ingelheim (Germany)Boehringer Ingelheim (United Kingdom)
TS

About

Thomas Seck is an author at Heidelberg University specializing in medicine, osteoporosis, and bone metabolism.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

369

2

Health Sciences

4

4

158

3

Engineering

1

1

24

4

Natural Sciences

1

1

38

5

Public Health

1

1

81

Thomas Seck

×

32

Publications

1.6K

Citations

22

H-Index

YearCitations

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

Thomas Seck, Michael A. Nauck, Sheila Sunga,

International Journal of Clinical Practice

2010

202

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial

Rosario Arechavaleta, Thomas Seck, Yong Chen,

Diabetes Obesity and Metabolism

2010

163

Binding of Filamin to the C-terminal Tail of the Calcitonin Receptor Controls Recycling

Thomas Seck, Roland Baron, William C. Horne

Journal of Biological Chemistry

2003

100

Concentration of Transforming Growth Factor Beta in Human Bone Tissue: Relationship to Age, Menopause, Bone Turnover, and Bone Volume

Johannes Pfeilschifter, Ingo Diel, Beate Scheppach,

Journal of Bone and Mineral Research

1998

90

The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

Charles A. Reasner, Leann Olansky, Thomas Seck,

Diabetes Obesity and Metabolism

2011

90

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher,

Cardiovascular Diabetology

2015

81

Association of Transforming Growth Factor-b1 (TGFb1) T29?C Gene Polymorphism with Bone Mineral Density (BMD), Changes in BMD, and Serum Concentrations of TGF-b1 in a Population-Based Sample of Postmenopausal German Women

V. Hinke, Thomas Seck, C. Clanget,

Calcified Tissue International

2001

81

Concentration of Insulin-Like Growth Factor (IGF)-I and -II in Iliac Crest Bone Matrix from Pre- and Postmenopausal Women: Relationship to Age, Menopause, Bone Turnover, Bone Volume, and Circulating IGFs1

Thomas Seck, Beate Scheppach, S.H. Scharla,

The Journal of Clinical Endocrinology & Metabolism

1998

79

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

Michael Lehrke, Nikolaus Marx, Sanjay Patel,

Clinical Therapeutics

2014

60

A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

Mark Kipnes, Priscilla Hollander, Ken Fujioka,

Diabetes Obesity and Metabolism

2009

53

Page 1